Reilly Herbert Faulkner III boosted its stake in shares of Dentsply Sirona (NASDAQ:XRAY) by 2.8% during the 1st quarter, HoldingsChannel.com reports. The firm owned 75,624 shares of the medical instruments supplier’s stock after acquiring an additional 2,052 shares during the period. Reilly Herbert Faulkner III’s holdings in Dentsply Sirona were worth $3,805,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently modified their holdings of XRAY. Bank of Montreal Can increased its holdings in Dentsply Sirona by 6.1% during the 4th quarter. Bank of Montreal Can now owns 211,583 shares of the medical instruments supplier’s stock worth $13,929,000 after purchasing an additional 12,211 shares during the period. National Pension Service increased its holdings in Dentsply Sirona by 9.5% during the 4th quarter. National Pension Service now owns 251,674 shares of the medical instruments supplier’s stock worth $16,568,000 after purchasing an additional 21,906 shares during the period. Creative Planning increased its holdings in Dentsply Sirona by 33.8% during the 4th quarter. Creative Planning now owns 14,758 shares of the medical instruments supplier’s stock worth $971,000 after purchasing an additional 3,724 shares during the period. Schwab Charles Investment Management Inc. increased its holdings in Dentsply Sirona by 3.2% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 795,363 shares of the medical instruments supplier’s stock worth $52,359,000 after purchasing an additional 24,585 shares during the period. Finally, Oakbrook Investments LLC purchased a new stake in Dentsply Sirona during the 4th quarter worth about $589,000. Institutional investors own 99.60% of the company’s stock.
In other news, CFO Nicholas W. Alexos bought 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 9th. The stock was purchased at an average cost of $44.71 per share, with a total value of $2,235,500.00. Following the transaction, the chief financial officer now directly owns 25,411 shares in the company, valued at $1,136,125.81. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Donald M. Jr. Casey bought 22,500 shares of the firm’s stock in a transaction that occurred on Wednesday, May 9th. The stock was purchased at an average cost of $44.52 per share, with a total value of $1,001,700.00. Following the completion of the transaction, the chief executive officer now owns 92,408 shares in the company, valued at $4,114,004.16. The disclosure for this purchase can be found here. 1.93% of the stock is owned by corporate insiders.
Dentsply Sirona (NASDAQ:XRAY) last announced its earnings results on Sunday, May 6th. The medical instruments supplier reported $0.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.42 by $0.03. The firm had revenue of $956.10 million during the quarter, compared to analysts’ expectations of $942.20 million. Dentsply Sirona had a positive return on equity of 8.63% and a negative net margin of 38.32%. The business’s revenue was up 6.2% on a year-over-year basis. During the same period in the prior year, the firm earned $0.49 EPS. research analysts forecast that Dentsply Sirona will post 2.58 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Friday, July 13th. Investors of record on Friday, June 29th will be given a $0.0875 dividend. The ex-dividend date of this dividend is Thursday, June 28th. This represents a $0.35 dividend on an annualized basis and a dividend yield of 0.73%. Dentsply Sirona’s dividend payout ratio (DPR) is presently 13.16%.
Several equities research analysts have weighed in on the company. Stifel Nicolaus restated a “buy” rating and set a $57.00 price target (down previously from $67.00) on shares of Dentsply Sirona in a report on Tuesday, May 8th. Robert W. Baird lowered their price objective on Dentsply Sirona to $71.00 and set an “outperform” rating for the company in a research report on Tuesday, May 8th. Zacks Investment Research cut Dentsply Sirona from a “hold” rating to a “sell” rating in a research report on Friday, May 11th. Deutsche Bank lowered their price objective on Dentsply Sirona to $55.00 and set a “buy” rating for the company in a research report on Wednesday. Finally, ValuEngine raised Dentsply Sirona from a “strong sell” rating to a “sell” rating in a research report on Wednesday. Four research analysts have rated the stock with a sell rating, four have given a hold rating and nine have issued a buy rating to the company’s stock. Dentsply Sirona has an average rating of “Hold” and an average price target of $62.79.
Dentsply Sirona Company Profile
DENTSPLY SIRONA Inc designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise dental hand pieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers.
Want to see what other hedge funds are holding XRAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dentsply Sirona (NASDAQ:XRAY).
Receive News & Ratings for Dentsply Sirona Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dentsply Sirona and related companies with MarketBeat.com's FREE daily email newsletter.